Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients

Abstract In this commentary, we address a paper published by Johnson et al. by assessing the robustness of their method to discover diagnostic biomarkers in Alzheimer’s disease (AD). In addition, we examine how these newly discovered and previously discovered biomarkers, can play a role in assisting...

Full description

Bibliographic Details
Main Authors:	Miyo K. Chatanaka, Ioannis Prassas, Eleftherios P. Diamandis
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	BMC Medicine
Subjects:	Alzheimer’s disease Biomarker Non-invasive SMOC1 Neuropentraxin Diagnostic test
Online Access:	https://doi.org/10.1186/s12916-024-03270-w

Similar Items

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease
by: Mohammad Arastoo, et al.
Published: (2020-11-01)

Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity
by: Frederik T. Larsen, et al.
Published: (2023-02-01)

Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
by: Liding Zhang, et al.
Published: (2022-01-01)

Effect of Thrombin on the Metabolism and Function of Murine Macrophages
by: Ürün Ukan, et al.
Published: (2022-05-01)

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease
by: Janne Marieke Herden, et al.
Published: (2023-06-01)

The meaning of blood and cerebrospinal fluid biomarkers in early diagnosis of Alzheimer's disease
by: Julita Szarpak, et al.
Published: (2020-09-01)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
by: Henrik Zetterberg, et al.
Published: (2021-02-01)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
by: Alain D. Dekker, et al.
Published: (2017-01-01)

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer’s disease
by: Shahzad Ahmad, et al.
Published: (2020-10-01)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
by: Johanna Nilsson, et al.
Published: (2021-01-01)

Amyloid‐beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome
by: Ioanna Stylianaki, et al.
Published: (2020-07-01)

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
by: Donovan A. McGrowder, et al.
Published: (2021-02-01)

What are NLRP3-ASC specks? an experimental progress of 22 years of inflammasome research
by: Abhinit Nagar, et al.
Published: (2023-07-01)

Lactoferrin in cerebrospinal fluid and saliva is not a diagnostic biomarker for Alzheimer's disease in a mixed memory clinic population
by: Helena Sophia Gleerup, et al.
Published: (2021-05-01)

Role of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
by: Thuy Trang Nguyen, et al.
Published: (2020-05-01)

The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
by: Sarah Westwood, et al.
Published: (2017-04-01)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
by: Sebastian Palmqvist, et al.
Published: (2019-12-01)

Downregulation of SMOC1 is associated with progression of colorectal traditional serrated adenomas
by: Hironori Aoki, et al.
Published: (2024-03-01)

Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
by: Joke Temmerman, et al.
Published: (2023-07-01)

Anaemia and cerebrospinal fluid biomarkers of Alzheimer’s pathology in cognitively normal elders: the CABLE study
by: Xin-Yu Yang, et al.
Published: (2021-11-01)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
by: George P. Paraskevas, et al.
Published: (2021-09-01)

SMOC can act as both an antagonist and an expander of BMP signaling
by: J Terrig Thomas, et al.
Published: (2017-03-01)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
by: Koen Delmotte, et al.
Published: (2021-04-01)

Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer’s Disease in Amnestic Mild Cognitive Impairment
by: Jung Eun Park, et al.
Published: (2019-03-01)

Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer’s Disease and Frontotemporal Dementia
by: Lourdes Álvarez-Sánchez, et al.
Published: (2023-01-01)

Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
by: Bianca A. Trombetta, et al.
Published: (2024-01-01)

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
by: Petar Podlesniy, et al.
Published: (2020-08-01)

Effect of renal function on the diagnostic performance of plasma biomarkers for Alzheimer’s disease
by: Bin Zhang, et al.
Published: (2023-03-01)

Heavy Metals and Essential Metals Are Associated with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
by: Mirjana Babić Leko, et al.
Published: (2022-12-01)

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
by: Matthias Pawlowski, et al.
Published: (2017-07-01)

Objective Physical Function in the Alzheimer’s Disease Continuum: Association with Cerebrospinal Fluid Biomarkers in the ALBION Study
by: Stefanos N. Sampatakakis, et al.
Published: (2023-09-01)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
by: Eline A.J. Willemse, et al.
Published: (2018-01-01)

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer’s disease and frontotemporal dementia
by: Shreyasee Das, et al.
Published: (2023-03-01)

Diagnostic Biomarkers for Alzheimer’s Disease Using Non-Invasive Specimens
by: Maria Paraskevaidi, et al.
Published: (2020-06-01)

Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
by: Cristina d’Abramo, et al.
Published: (2020-09-01)

Alzheimer disease pathology and the cerebrospinal fluid proteome
by: Loïc Dayon, et al.
Published: (2018-07-01)

Cerebrospinal Fluid Biomarkers for Differentiation of Frontotemporal Lobar Degeneration from Alzheimer’s Disease
by: David J Irwin, et al.
Published: (2013-02-01)

Aβ42 as a Biomarker of Alzheimer’s Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
by: Silvia Boschi, et al.
Published: (2022-12-01)

Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer’s Disease
by: Da Hae Jung, et al.
Published: (2022-07-01)

Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer’s Disease in Clinical Practice: An Illustration with 3 Case Reports
by: Diane Slats, et al.
Published: (2010-02-01)